Alfresa Holdings Corporation (ALFRY)
OTCMKTS
· Delayed Price · Currency is USD
15.99
0.00 (0.00%)
May 27, 2025, 4:00 PM EDT
Alfresa Holdings Revenue
In the fiscal year ending March 31, 2025, Alfresa Holdings had annual revenue of 2.96T JPY with 3.59% growth. Alfresa Holdings had revenue of 698.73B in the quarter ending March 31, 2025, with 2.95% growth.
Revenue
2,961.05B JPY
Revenue Growth
+3.59%
P/S Ratio
0.12
Revenue / Employee
236.56M JPY
Employees
12,517
Market Cap
2.45B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 2,961.05B | 102.55B | 3.59% |
Mar 31, 2024 | 2,858.50B | 162.43B | 6.02% |
Mar 31, 2023 | 2,696.07B | 110.43B | 4.27% |
Mar 31, 2022 | 2,585.64B | -17.53B | -0.67% |
Mar 31, 2021 | 2,603.17B | -95.34B | -3.53% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |